Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tomohiro Ohigashi has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dose Optimization Design for Randomized Phase II Trials With Toxicity and Efficacy Endpoints

    by Ryuta Tabata, Tomohiro Ohigashi, Takashi Sozu

    Several study designs for identifying optimal biological dose (OBD) have been proposed for phase I, II, and I/II clinical trials, considering toxicity and efficacy of anticancer drugs, especially molecular‐targeted therapies and immune checkpoint inhibitors. Among these, the multiple‐dose randomized phase II trial (MERIT) design selects OBD candidates using hypothesis testing for toxicity and efficacy outcomes. However, it does not consistently control the type I error rate below the significance level, as the null hypothesis is defined only at specific points in a two‐dimensional null space. To address this limitation, we developed a design treating toxicity and efficacy as co‐primary endpoints, ensuring strict dose‐level type I error control across the entire null space. A Bonferroni correction addressed multiplicity in dose selection, providing overall type I error control. Unlike the existing method, the rejection region is determined analytically rather than by simulation, reducing computational costs. The type I error rate of the existing method exceeds the significance level in regions outside points considered in its sample size calculation. By contrast, the proposed method maintains the type I error rate below the significance level across the null space, though conservatively due to the co‐primary endpoint framework and Bonferroni adjustment. Required sample sizes of the proposed method tend to be larger than those of the existing one.

  • Dynamic Prediction of Analysis Timing in Clinical Trials Using Joint Models of Longitudinal and Time‐to‐Event Data

    by Ryunosuke Machida, Kentaro Sakamaki, Tomohiro Ohigashi, Takashi Sozu

    In confirmatory clinical trials with a time‐to‐event endpoint, the timing of the analysis is often determined based on the observed number of events. In such event‐driven trials, the analysis timing is inherently uncertain, making its accurate prediction crucial for optimizing trial costs, personnel allocation, and resource management. Although various methods for predicting analysis timing have been extensively studied under different assumptions, these approaches predominantly rely on data pertaining to the primary endpoint when estimating the time‐to‐event distribution. To the best of our knowledge, no existing method incorporates longitudinally measured data, such as prostate‐specific antigen (PSA) levels in prostate cancer trials. We developed a method for predicting analysis timing within the framework of dynamic prediction using joint models that account for longitudinally measured covariates and time‐to‐event outcomes. Furthermore, we assessed the prediction performance by comparing it against two alternative methods based on the degree of covariate data: (1) a method without covariates, (2) a method using only baseline covariates, and (3) the proposed method using baseline and longitudinally measured covariates. Numerical experiments demonstrated that the proposed method enhances the accuracy of analysis timing predictions compared with methods that do not utilize longitudinally measured covariates. The proposed method is valuable for accurately predicting analysis timing when longitudinally measured covariates are available.


  • Open Access

    Triple-drug therapy with Goreisan, tranexamic acid and carbazochrome sodium sulfonate hydrate to prevent recurrence after chronic subdural haematoma surgery: a multicentre, randomised, controlled trial protocol

    by Haruka Negishi, Koji Hirata, Hitoshi Aiyama, Keishi Fujita, Yoji Komatsu, Noriyuki Kato, Yasushi Shibata, Kyoji Tsuda, Tomosato Yamazaki, Masayuki Sato, et al.

    Introduction: Chronic subdural haematoma (CSDH) is a common neurosurgical condition in older adults, with a recurrence rate of approximately 7.1–13% after burr-hole drainage. Although surgical adjuncts such as subdural drains and middle meningeal artery embolisation may reduce recurrence, these are not suitable for all patients. Pharmacological strategies, including tranexamic acid, Goreisan and carbazochrome sodium sulfonate hydrate, have shown potential, but high-level evidence remains lacking. A prior retrospective study suggested that a triple oral regimen combining these agents may reduce recurrence. This randomised controlled trial aims to evaluate its efficacy and safety. Methods and analysis: This is a prospective, multicentre, open-label, randomised controlled trial conducted across six hospitals in Ibaraki, Japan. A total of 180 patients undergoing first-time burr-hole surgery for CSDH will be randomised 1:1 to receive either triple therapy (Goreisan 7.5 g/day, carbazochrome sodium sulfonate hydrate 90 mg/day and tranexamic acid 750 mg/day for up to 90 days) or standard postoperative care. The primary outcome is recurrence requiring reoperation within 90 days. Secondary outcomes include time to recurrence and haematoma volume reduction on serial CT imaging. All analyses will follow the intention-to-treat principle, using logistic regression, Cox proportional hazards models and mixed-effects models. Ethics and dissemination: Written, informed consent will be obtained from all participants at each participating hospital by trained staff from that hospital. The trial protocol has been approved by the ethics committee of the University of Tsukuba Hospital (approval no. TCRB23-025) and the Institutional Review Boards of all participating centres. Study findings will be disseminated through presentations at scientific conferences and publications in peer-reviewed journals. A summary of the results will also be provided to participating institutions and made publicly available in accordance with the BMJ Open data sharing policy. Trial registration number: jRCTs031240007.


  • Open Access

    Nonparametric Bayesian approach for dynamic borrowing of historical control data

    by Tomohiro Ohigashi, Kazushi Maruo, Takashi Sozu, Masahiko Gosho

    When incorporating historical control data into the analysis of current randomized controlled trial data, it is critical to account for differences between the datasets. When the cause of difference is an unmeasured factor and adjustment for only observed covariates is insufficient, it is desirable to use a dynamic borrowing method that reduces the impact of heterogeneous historical controls. We propose a nonparametric Bayesian approach that addresses between-trial heterogeneity and allows borrowing historical controls homogeneous with the current control. Additionally, to emphasize conflict resolution between historical controls and the current control, we introduce a method based on the dependent Dirichlet process (DP) mixture. The proposed methods can be implemented using the same procedure, regardless of whether the outcome data comprise aggregated study-level data or individual participant data. We also develop a novel index of similarity between the historical and current control data, based on the posterior distribution of the parameter of interest. We conduct a simulation study and analyze clinical trial examples to evaluate the performance of the proposed methods compared to existing methods. The proposed method, based on the dependent DP mixture, can accurately borrow from homogeneous historical controls while reducing the impact of heterogeneous historical controls compared to the typical DP mixture. The proposed methods outperform existing methods in scenarios with heterogeneous historical controls, in which the meta-analytic approach is ineffective.


  • Potential Bias Models With Bayesian Shrinkage Priors for Dynamic Borrowing of Multiple Historical Control Data

    by Tomohiro Ohigashi, Kazushi Maruo, Takashi Sozu, Ryo Sawamoto, Masahiko Gosho

    When multiple historical controls are available, it is necessary to consider the conflicts between current and historical controls and the relationships among historical controls. One of the assumptions concerning the relationships between the parameters of interest of current and historical controls is known as the “Potential biases.” Within the “Potential biases” assumption, the differences between the parameters of interest of the current control and of each historical control are defined as “potential bias parameters.” We define a class of models called “potential biases model” that encompass several existing methods, including the commensurate prior. The potential bias model incorporates homogeneous historical controls by shrinking the potential bias parameters to zero. In scenarios where multiple historical controls are available, a method that uses a horseshoe prior was proposed. However, various other shrinkage priors are also available. In this study, we propose methods that apply spike‐and‐slab, Dirichlet–Laplace, and spike‐and‐slab lasso priors to the potential bias model. We conduct a simulation study and analyze clinical trial examples to compare the performances of the proposed and existing methods. The horseshoe prior and the three other priors make the strongest use of historical controls in the absence of heterogeneous historical controls and reduce the influence of heterogeneous historical controls in the presence of a few historical controls. Among these four priors, the spike‐and‐slab prior performed the best for heterogeneous historical controls.


  • Open Access

    Effectiveness of an online support program to help female cancer patients manage their health and illness: Protocol for a randomized controlled trial

    by Michiyo Mizuno, Ikuko Chiba, Toru Mukohara, Miki Kondo, Kazushi Maruo, Tomohiro Ohigashi, Miki Naruo, Yoshihiro Asano, Tatsuya Onishi, Hiroshi Tanabe, et al.


  • Open Access

    A Smartphone Healthcare Application, CALO mama Plus, to Promote Weight Loss: A Randomized Controlled Trial

    by Yoshio Nakata, Hiroyuki Sasai, Masahiko Gosho, Hiroyuki Kobayashi, Yutong Shi, Tomohiro Ohigashi, Shinichiro Mizuno, Chiaki Murayama, Satomi Kobayashi, Yuki Sasaki

    Mobile applications are increasingly used in healthcare. We have developed a smartphone healthcare application, CALO mama Plus, that can register daily diet, exercise, mood, and sleep quality, calculate dietary intake, and provide advice using artificial intelligence technology. This 3-month randomized controlled trial tested the hypothesis that CALO mama Plus could promote body weight reduction in Japanese adults with overweight or obesity. We recruited office workers as participants. The key eligibility criteria were an age of 20–65 years and a body mass index of 23–40 kg/m2. The primary outcome was body weight change over 3 months. We enrolled 141 participants and randomly assigned them to the intervention (n = 72) and control (n = 69) groups. The intervention group used CALO mama Plus, and the control group did not receive any intervention. The change in body weight was −2.4 ± 4.0 kg and −0.7 ± 3.3 kg in the intervention and control groups, respectively. An analysis of covariance adjusted for related variables showed a significant between-group difference in body weight change (−1.60 kg; 95% confidence interval −2.83 to −0.38; p = 0.011). The present study suggests that CALO mama Plus effectively promotes weight loss.


  • Open Access

    Identification of High-Risk Groups in Urinalysis: Lessons from the Longitudinal Analysis of Annual Check-Ups

    by Keiichi Matsuzaki, Tomohiro Ohigashi, Takashi Sozu, Mami Ishida, Daisuke Kobayashi, Hitoshi Suzuki, Yusuke Suzuki, Takashi Kawamura

    Background: For effective screening in urinalysis, information on high-risk groups is needed; however, there is a lack of evidence in young adults in particular. The aim of this study was to provide information on urinalysis in young adults and to identify high-risk groups of urinalyses using multi-year data obtained from annual large-scale check-ups. Method: We used annual health check-up data collected from 2011 to 2016 at Kyoto University in Japan. Eligible participants were those aged 18–39 years who underwent annual health check-ups for four consecutive years between 2011 and 2016. We conducted descriptive analyses and calculated the risk ratios (RRs) for urinary abnormalities in the fourth year of urinalysis. Results: In total, 13,640 participants (10,877 men, 79.7%) met the eligibility criteria. The mean prevalence rates of proteinuria, haematuria and glucosuria were 1.61% (men: 1.63%; women: 1.53%), 1.48% (men: 0.53%; women: 5.22%) and 0.46% (men: 0.52%; women: 0.25%), respectively. Participants with urinary abnormalities at least once in the initial 3 years had a higher risk of urinary abnormalities in the fourth year than participants with no abnormal findings in the initial 3 years; the risk ratios (RRs) of proteinuria, haematuria and glucosuria were 3.5 (95% confidence interval (CI) = 3.2–3.7), 12.2 (95% CI = 11.7–12.7) and 42.6 (95% CI = 37.7–48.1), respectively. The RRs of all urinary abnormalities in the fourth year increased as the frequency of urinary abnormalities over the preceding 3 years increased. In haematuria, differences of the RR were observed between men and women. Conclusion: We clarified the prevalence of urinary abnormalities in young adults and high-risk groups of urinary abnormalities. Our findings support the need for multi-year annual urinalysis.


  • Using horseshoe prior for incorporating multiple historical control data in randomized controlled trials

    by Tomohiro Ohigashi, Kazushi Maruo, Takashi Sozu, Masahiko Gosho

    Meta-analytic approaches and power priors are often used to incorporate historical controls into the analysis of a current randomized controlled trial. In this study, we propose a method for incorporating multiple historical controls based on a horseshoe prior, which is a type of global–local shrinkage prior. The method assumes that historical controls follow the same distribution as the current control. In the case in which only a few historical controls are heterogeneous, we consider them to follow a potentially biased distribution from the distribution of the current control. We analyze two clinical trial examples with binary and time-to-event endpoints and conduct simulation studies to compare the performance of the proposed and existing methods. In the analysis of the clinical trial example, the posterior standard deviation of the treatment effect is decreased by the proposed method by considering the bias between the current control and heterogeneous historical control. In the scenarios in which the current and historical controls follow the same distribution, the statistical power using the proposed method is higher than that using existing methods. The proposed method is advantageous when few or no heterogeneous historical controls are expected.